Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-6051b in Japanese patients with ROS1/NTRK+ solid tumors
NCT02675491Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2016
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taletrectinib in solid tumor (advanced stage), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: number and severity of adverse events. Started Feb 2016; status: completed.
02
Drugs
taletrectinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02675491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675491.